https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-29 / Gut 2007 Sep;56(9):1275-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-29 / Gut 2007 Sep;56(9):1275-822007-03-29 00:00:002019-02-15 09:23:45Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-15 / Clin. Exp. Immunol. 2007 Jun;148(3):494-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-15 / Clin. Exp. Immunol. 2007 Jun;148(3):494-5002007-03-15 00:00:002019-02-15 08:37:38Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-402007-03-15 00:00:002021-11-15 15:39:28Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-14 / J Transl Med 2007 Mar;5:16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-14 / J Transl Med 2007 Mar;5:162007-03-14 00:00:002007-03-14 00:00:00Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Oncol. Rep. 2007 Mar;17(3):653-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Oncol. Rep. 2007 Mar;17(3):653-92007-03-01 00:00:002019-02-15 08:35:07Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Expert Rev Anticancer Ther 2007 Mar;7(3):275-832007-03-01 00:00:002019-02-15 08:37:33Dendritic cell vaccines for leukemia patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-62007-03-01 00:00:002019-02-15 09:19:43Dendritic cell-based immunotherapy of malignant melanoma: success and limitations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-42007-03-01 00:00:002019-02-15 09:24:09Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-672007-03-01 00:00:002019-02-15 09:22:10Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-52007-03-01 00:00:002019-02-15 09:22:11Oncolytic virus therapy–foreword
